Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology. CTCs are present across all melanoma stages, with a significant ...
Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...
Medical Device Network on MSN
Quest launches flow cytometry MRD test for myeloma
Quest expects the new blood test will support response monitoring in clinical trials.
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...
Immunotherapies against cancer rely on the functionality of effector cells against a variety of tumors. Effector cells, including CD4, CD8 T-Cells and Natural Killer (NK) cells, recognize tumors by ...
FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.
Combining statistical modeling with flow cytometry enables reliable, high-throughput quantification of division asymmetry in live cells, revealing how partitioning noise may shape tumor cell ...
Role for immune checkpoint blockade in BRCA2-mutant prostate cancer. This is an ASCO Meeting Abstract from the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. This abstract does not include a full ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results